Catalyst Pharmaceuticals (CPRX) Gross Margin (2019 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Gross Margin of 90.31% for Q1 2026, up 8.92% on a QoQ basis from 82.91% in Q4 2025, and up 298.0% year-over-year from 22.69% in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Gross Margin (2019 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Gross Margin history runs 8 years deep, the most recent figure standing at 90.31% for Q1 2026.
- Quarterly Gross Margin rose 298.0% year-over-year to 90.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 85.96% (down 16.0% YoY) and the FY2025 annual result came in at 85.19%, down 81.0% from the prior year.
- Gross Margin was 90.31% for Q1 2026 at Catalyst Pharmaceuticals, up from 82.91% in the prior quarter.
- Across five years, Gross Margin topped out at 90.31% in Q1 2026 and bottomed at 81.57% in Q4 2022.
- A 5-year average of 85.91% and a median of 85.94% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin sank 211 bps — and 2023, when it jumped 413 bps.
- Catalyst Pharmaceuticals' Gross Margin stood at 81.57% in 2022, then grew by 5 bps to 85.7% in 2023, then slipped by 1 bps to 84.74% in 2024, then retreated by 2 bps to 82.91% in 2025, then climbed by 9 bps to 90.31% in 2026.
- Business Quant data shows CPRX's Gross Margin at 90.31% in Q1 2026, 82.91% in Q4 2025, and 84.73% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 90.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90.31% |
| Dec 31, 2025 | 82.91% |
| Sep 30, 2025 | 84.73% |
| Jun 30, 2025 | 85.94% |
| Mar 31, 2025 | 87.33% |
| Dec 31, 2024 | 84.74% |
| Sep 30, 2024 | 85.02% |
| Jun 30, 2024 | 87.45% |
| Mar 31, 2024 | 87.29% |
| Dec 31, 2023 | 85.70% |
| Sep 30, 2023 | 86.20% |
| Jun 30, 2023 | 87.90% |
| Mar 31, 2023 | 88.35% |
| Dec 31, 2022 | 81.57% |
| Sep 30, 2022 | 83.12% |
| Jun 30, 2022 | 85.61% |
| Mar 31, 2022 | 86.33% |
| Dec 31, 2021 | 80.82% |
| Sep 30, 2021 | 85.23% |
| Jun 30, 2021 | 87.50% |